Medtronic has secured approval from the US Food and Drug Administration (FDA) for its TrailBlazer angled peripheral support catheter to be used in the peripheral vascular system.
Support catheters such as TrailBlazer are used frequently used in endovascular procedures for the treatment of complex peripheral artery disease (PAD).
Medtronic said TrailBlazer has been designed to support a guide wire during access to the peripheral arteries and in providing delivery solutions and diagnostic agents.
The catheter has a braided stainless steel shaft for robust pushability along with 25 and 30 degree angled tapered tip to access cross complex lesions.
To improve visibility of physician, each of the 0.014”, 0.018” and 0.035” guidewire compatible devices has been designed with three radiopaque marker bands and a radiopaque shaft.
Also, both the 0.014” and 0.018” TrailBlazer angled support catheter can coaxially fit through the 0.035” support catheter for higher reach and pushability.
Medtronic Aortic & Peripheral Vascular division part of Peripheral business vice president and general manager Mark Pacyna said: "Medtronic is committed to providing physicians with meaningful innovations and therapy choices to enhance their peripheral treatment algorithm.
"Working with physicians, we have extended the Medtronic TrailBlazer support catheter portfolio to offer a broad suite of angled options for treatment of complex lesions both above and below the knee."